Funding for this research was provided by:
National Institute on Drug Abuse (R01DA034086)
Received: 3 March 2020
Accepted: 26 November 2020
First Online: 4 December 2020
Ethics approval and consent to participate
: Our study protocol was approved by the Institutional Review Boards (IRBs) of Albert Einstein College of Medicine and Prisma Health. Participation in this study was entirely voluntary. Before undertaking any research activity, written informed consent was obtained from every study participant. The study was conducted in accordance with Good Clinical Practice and the ethical principles that originated in the Declaration of Helsinki. The parent study, a randomized clinical trial was registered in clinical trial.gov under the number NCT01857245.
: Not applicable.
: All authors report receiving grant funding from the National Institutes of Health (NIH). Dr. Litwin has served on advisory board for Merck Pharmaceuticals, AbbVie and Gilead Sciences. He has received research grants from Merck Pharmaceuticals and Gilead Sciences.